Elisa De Paolis1, Angelo Minucci1, Maria De Bonis1, Giovanni Luca Scaglione2, Jacopo Gervasoni1, Aniello Primiano1, Pietro Manuel Ferraro3, Daniele Cappellani4, Claudio Marcocci4, Giovanni Gambaro3, Ettore Capoluongo5. 1. Polo Scienze delle Immagini, di Laboratorio ed Infettivologiche, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli, Roma, Italy. 2. Laboratory of Molecular Oncology, "Giovanni Paolo II" Foundation, Catholic University of Sacred Heart, Campobasso, Italy. 3. Polo di Scienze Reumatologiche, Dermatologiche, Immuno-Allergologiche, Urologiche e Nefrologiche, Istituto di Medicina Interna e Geriatria. Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli, Roma, Italy. 4. Department of Clinical and Experimental Medicine, Section of Endocrinology, University of Pisa, Pisa, Italy. 5. Laboratory of Clinical Pathology and Advanced Molecular Diagnostics, Istituto Dermopatico dell'Immacolata -IRCCS, Rome, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli, Roma, Italy. Electronic address: e.capoluongo@idi.it.
Abstract
INTRODUCTION: Loss-of-function mutations in cytochrome P450 family 24 subfamily A member 1 (CYP24A1) gene are associated with Idiopathic Infantile Hypercalcemia (IIH) and adult kidney stone disease. The enzyme deficiency leads to an impaired vitamin D catabolism pathway, resulting in a syndrome characterized by recurrent hypercalcemia, hypercalciuria and suppressed parathyroid hormone (PTH) levels. In these patients, the genetic evaluation of CYP24A1 is an important diagnostic tool, allowing the definitive diagnosis of IIH. METHODS: A rapid CYP24A1 gene testing based on High Resolution Melting Analysis (HRMA) was designed in order to detect the CYP24A1 c.428_430delAAG (p.Glu143del), a recurrent IIH-associated variant. RESULTS: HRMA method was able to identify c.428_430delAAG genotypes evaluating melting curve shape and melting temperature (Tm). Heterozygous samples exhibited a typical melting profile while homozygous samples showed a specific Tm shift. CONCLUSIONS: We provide evidence about application of HRMA in unambiguous genotyping of the CYP24A1 c.428_430delAAG variant, making this method useful in clinical molecular diagnostics. This approach opens the way to a helpful molecular analysis of CYP24A1 gene in IIH diagnosis, to an improved pharmacological treatment strategy and to a reduced risk of recurrent stones and worsening nephrocalcinosis.
INTRODUCTION: Loss-of-function mutations in cytochrome P450 family 24 subfamily A member 1 (CYP24A1) gene are associated with Idiopathic Infantile Hypercalcemia (IIH) and adult kidney stone disease. The enzyme deficiency leads to an impaired vitamin D catabolism pathway, resulting in a syndrome characterized by recurrent hypercalcemia, hypercalciuria and suppressed parathyroid hormone (PTH) levels. In these patients, the genetic evaluation of CYP24A1 is an important diagnostic tool, allowing the definitive diagnosis of IIH. METHODS: A rapid CYP24A1 gene testing based on High Resolution Melting Analysis (HRMA) was designed in order to detect the CYP24A1c.428_430delAAG (p.Glu143del), a recurrent IIH-associated variant. RESULTS: HRMA method was able to identify c.428_430delAAG genotypes evaluating melting curve shape and melting temperature (Tm). Heterozygous samples exhibited a typical melting profile while homozygous samples showed a specific Tm shift. CONCLUSIONS: We provide evidence about application of HRMA in unambiguous genotyping of the CYP24A1c.428_430delAAG variant, making this method useful in clinical molecular diagnostics. This approach opens the way to a helpful molecular analysis of CYP24A1 gene in IIH diagnosis, to an improved pharmacological treatment strategy and to a reduced risk of recurrent stones and worsening nephrocalcinosis.
Authors: Maria De Bonis; Elisa De Paolis; Maria Elisabetta Onori; Giorgia Mazzuccato; Antonio Gatto; Pietro Ferrara; Pietro Manuel Ferraro; Andrea Urbani; Angelo Minucci Journal: Mol Biol Rep Date: 2021-04-17 Impact factor: 2.316
Authors: Nina Lenherr-Taube; Edwin J Young; Michelle Furman; Yesmino Elia; Esther Assor; David Chitayat; Tami Uster; Susan Kirwin; Katherine Robbins; Kathleen M B Vinette; Alan Daneman; Christian R Marshall; Carol Collins; Kenneth Thummel; Etienne Sochett; Michael A Levine Journal: J Clin Endocrinol Metab Date: 2021-09-27 Impact factor: 6.134